Quick Facts

• Main Use: Supports the evaluation of adrenal gland function.
• Therapeutic Domain: Used as a diagnostic agent in the assessment of a specific condition where the adrenal glands may not release adequate cortisol.
• Clinical Goal: Facilitates the screening process for adrenocortical insufficiency in adults and children.

---

Cosyntropin is utilized solely as a diagnostic agent to support the evaluation of the adrenal cortex's response. Its principal clinical application is in the screening process for adrenocortical insufficiency, a condition where the body's adrenal glands may not release appropriate levels of the hormone cortisol.

The use of this agent helps healthcare providers determine the functional capacity of the adrenal glands. It facilitates the assessment of whether the adrenal glands are capable of a normal cortisol response. Cosyntropin is administered as part of the rapid adrenocorticotropic hormone (ACTH) stimulation test, which is a standard clinical procedure for detecting potential adrenal insufficiency.

This agent is part of a thorough diagnostic work-up and is intended for use in combination with other clinical and laboratory tests to inform the diagnosis in patients.

Eligibility Map: Official Regulatory Information

The eligibility for Cosyntropin, a diagnostic agent, is strictly defined by government regulatory documents, outlining who is approved for use and who must be excluded or treated with caution.

Category	Population / Condition	Regulatory Wording / Status
Contraindicated Populations	Hypersensitivity to Cosyntropin or Excipients	Contraindicated (Includes history of previous adverse reactions)
Approved Age Groups	Adults and Pediatric Patients (Birth to 17 years)	Approved for Use (Safety and effectiveness established)
Use-Related Restrictions	Patients on Estrogen-Containing Drugs	Conditional Use (Requires discontinuation 4–6 weeks prior to testing to avoid inaccurate results)
	Patients on Glucocorticoids or Spironolactone	Conditional Use (Requires omitting the dose on the day of testing)
Pregnancy Eligibility	Pregnant Women	Conditional Use (Use only if clearly needed; potential benefit must justify risk)
Lactation Eligibility	Nursing Mothers	Caution (Unknown if excreted in human milk; caution should be exercised)

The regulatory profile enforces a single absolute non-eligibility rule: Cosyntropin is contraindicated in patients with a history of hypersensitivity to the drug or its components. Eligibility is established for all adult and pediatric patients for its diagnostic purpose. However, use is conditional on the management of concurrent medications, specifically estrogen-containing drugs and certain steroids, which must be discontinued or withheld as they may interfere with accurate cortisol measurements. For pregnant or nursing women, regulatory caution is advised due to limited data, restricting use to cases where the benefit clearly outweighs the potential risks.

Interactions with other medicines and products

The official interaction profile for Cosyntropin, a diagnostic agent, is primarily defined by medicinal products that interfere with the accurate measurement of plasma cortisol, the intended outcome of the test. This requires adherence to regulatory restrictions and timing rules.

Diagnostic Interference and Test Accuracy

Several drug classes are officially documented as affecting the diagnostic accuracy:

• Estrogen-containing drugs: These medications, including oral contraceptives, are officially noted to increase Cortisol Binding Globulin (CBG), which in turn elevates the measured plasma total cortisol level.
• Glucocorticoids: Both short-acting and long-acting forms may result in falsely elevated or lowered plasma cortisol levels, potentially compromising the test result.
• Spironolactone: This medication is officially documented to interfere with the test, possibly leading to falsely elevated plasma cortisol measurements.

Mandatory Administration Timing Rules

To ensure reliable test results, the official labeling mandates specific timing rules:

• Estrogen-containing drugs must be discontinued for four to six weeks before the test.
• Short-acting Glucocorticoids and Spironolactone require the omission of the pre-test dose on the day of the test. A longer discontinuation period may be necessary for long-acting Glucocorticoids.

Other Documented Interactions

A non-diagnostic pharmacodynamic interaction is noted with Diuretics. Co-administration may accentuate the electrolyte loss associated with diuretic therapy. No specific drug-drug combinations are formally listed as contraindicated for interaction purposes, and no specific CYP-enzyme or transporter-mediated metabolic interactions are documented in the official regulatory prescribing information.

The action of Cosyntropin is centered on its function as an agonist at the single, specific biological target: the Melanocortin 2 Receptor ( MC2 R), found exclusively on the adrenal cortex.

Cosyntropin directly engages the MC2 R, substituting for the endogenous signal, and initiates a cAMP signaling cascade inside the cell. The subsequent activation of Protein Kinase A (PKA) accelerates the core process of steroidogenesis by influencing key molecular steps required for converting cholesterol into corticosteroids.

This mechanism results in a rapid and temporary increase in the synthesis and secretion of cortisol and, to a lesser extent, aldosterone. This peripheral endocrine system stimulation bypasses central regulatory signals, producing a high-magnitude, acute surge in glucocorticoids. The resulting systemic physiological adjustment serves as a readout of the adrenal gland's steroidogenic capability.

Cosyntropin is used exclusively as a single-event diagnostic agent, administered through specific parenteral routes. The official use pattern is characterized by a precise dose, single frequency, and time-bound procedural steps for the rapid adrenocorticotropic hormone (ACTH) stimulation test.

---

Administration and Dosage

The medicine is supplied as an injectable product approved for use via intravenous (IV) injection or intramuscular (IM) injection. The standard dose for this rapid screening procedure is 0.25 mg for adults and pediatric patients 2 years of age and older.

Use Pattern and Timing

Cosyntropin is administered as a single-event dose and is not intended for repeated or long-term therapeutic regimens. The timing of administration is critical to the diagnostic protocol, as the procedure requires the collection of follow-up blood samples at set intervals, typically at 30 minutes and/or 60 minutes following the injection. For IV use, the dose is administered over a 2-minute period.

Age-Specific Dosing and Preparation

A specific adjustment exists for younger individuals: pediatric patients from birth to less than 2 years of age are administered a dose of 0.125 mg. The sterile powder form requires reconstitution with a compatible solution, such as 0.9% Sodium Chloride Injection. Furthermore, the solution must be clear and colorless before administration, and any unused portion of the product must be discarded immediately upon completion of the procedure.

Research evidence / Overview of studies for Cosyntropin

---

Evidence for Diagnostic Accuracy

Cosyntropin was studied for its intended use as a diagnostic agent in evaluating the adrenal gland's functional reserve. Research includes Randomized, Controlled Bioequivalence Studies that were conducted to evaluate whether the synthetic agent performs comparably to the original reference standard. Studies examine the adrenal cortex's output by measuring the Peak Serum Cortisol Concentration and the Cortisol Increment following administration.

The research exploring test utility includes Systematic Reviews and large Observational Cohort Studies that examined its Diagnostic Accuracy. Studies observed how well test results aligned with those from more comprehensive diagnostic procedures for Adrenocortical Insufficiency (AI). Research has described that its performance in identifying Primary AI was measured differently than its performance in Secondary/Central AI. The accuracy of test measurement is assessed differently in cases of very recent-onset insufficiency, given the timing of the condition.

---

Evidence in Special Patient Groups and Limitations

The research has monitored the agent’s use across distinct populations, including Adults and Children. Studies explored its role in cohorts of Critically Ill Patients, where conditions altering cortisol-carrying proteins are factors that researchers monitor during interpretation. Findings also describe patterns related to variations in cortisol response in infants depending on the dose used.

Because the test focuses on an acute response, studies primarily use an acute observation period of 30 to 60 minutes. Since the test is designed to measure an acute reaction, follow-up durations were limited in most trials; there is limited information for long-term outcomes. Research highlights that the consistency of evidence varies across studies concerning the optimal diagnostic cutoff values for serum cortisol. Additionally, the results apply only to the populations studied, and factors like a patient's underlying illness are monitored during the interpretation of test results.

Common questions about Cosyntropin (FAQ)

---

Q: How quickly does Cosyntropin start working in the body?

Cosyntropin is designed to be a rapid-acting diagnostic agent. According to clinical data and official labeling, increases in plasma cortisol concentrations are typically observed within approximately five minutes of injection in individuals with normal adrenal function.

---

Q: Is the use of Cosyntropin restricted for people with high blood pressure?

High blood pressure (hypertension) has been reported as an adverse reaction following the administration of Cosyntropin. However, while this condition is monitored, pre-existing high blood pressure is not listed as an absolute contraindication in the official regulatory labeling.

---

Q: Is Cosyntropin a steroid?

No, Cosyntropin is not a steroid. It is a synthetic peptide that acts as a mimic of the natural hormone ACTH. Its mechanism is to stimulate the adrenal glands to rapidly produce and secrete the body's own steroids, such as cortisol, which is the result measured in the diagnostic test.

---

Q: What happens if my ACTH test results are abnormal after using Cosyntropin?

The diagnostic test is used to evaluate the functional reserve of the adrenal glands. Stimulated plasma cortisol levels that fall below established cutoff values are suggestive of adrenocortical insufficiency, suggesting that the adrenal glands may not be responding adequately to the stimulus.

---

Q: Is it normal to feel a brief flush or warmth after the injection?

Yes, regulatory documents indicate that flushing (a brief feeling of warmth or redness) has been reported as an adverse effect following the administration of Cosyntropin. This is a recognized temporary effect that may occur.

---

Q: How accurate is the Cosyntropin stimulation test?

Regulatory warnings indicate that the accuracy of the test results can be affected by various factors. These include concurrent medications, such as estrogens or certain steroids, and certain medical conditions like cirrhosis or nephrotic syndrome that may alter cortisol-binding protein levels.

---

Q: Are there any long-term side effects associated with Cosyntropin use?

Cosyntropin is intended and approved for use as a single-event diagnostic procedure. As such, reported adverse effects in official documents are focused on immediate reactions, such as rash, swelling, and changes in heart rate or blood pressure. Information on long-term effects beyond the acute diagnostic period is limited.

---

Q: Is it possible to be allergic to Cosyntropin?

Yes, an allergic reaction is possible. Official prescribing information states that the drug is strictly contraindicated in anyone with a known history of hypersensitivity to the product. Rare but serious allergic reactions, including anaphylaxis, have been reported in post-marketing surveillance.

---

Q: What are the signs of a severe reaction to Cosyntropin to look out for?

Official safety documents report rare severe reactions, including anaphylaxis. These reactions are most likely to occur within 30 minutes of administration.

---

Q: What should be checked on lab tests after a Cosyntropin administration?

The purpose of the diagnostic procedure is to measure serum cortisol levels following the injection. Blood samples are typically collected at the start (baseline) and again at specific timed intervals, such as 30 or 60 minutes after the injection, to assess the adrenal response.

---

Q: Is Cosyntropin safe for pregnant or breastfeeding women?

For pregnancy, official product information indicates that it is not fully known if this drug can cause fetal harm. It should be administered only if the benefit is considered necessary. Regarding nursing mothers, it is unknown if the drug is excreted in human milk, and caution is advised by regulators.

---

Q: What body systems are most affected by Cosyntropin?

Cosyntropin is highly specific in its action. Its primary effect is on the adrenal cortex, where it binds to specific receptors to stimulate the production and secretion of adrenal steroids, such as cortisol.

---

Q: Does Cosyntropin contain any common allergens like gluten or lactose?

Official product documentation lists the active ingredient, Cosyntropin, and excipients like mannitol. Gluten and lactose are not specified as ingredients in the formula supplied as a sterile lyophilized powder.

---

Q: How is the potency of Cosyntropin measured?

Its potency is related to its ability to stimulate the adrenal cortex. Official clinical information states that the administered dose is established to provide the same maximal stimulation to the adrenal cortex as a larger dose of natural ACTH, ensuring a standardized diagnostic result.

Storage Conditions

Storage requirements for Cosyntropin are determined by the formulation. The lyophilized powder must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).

The liquid solution form requires refrigeration, with storage mandated between 2 C and 8 C (36 F and 46 F). Crucially, the liquid solution must be protected from light and must not be frozen.

Stability and Disposal

The product is supplied in single-dose vials, and the official labeling states that the reconstituted solution should not be retained. Any unused portion of both the powder and the liquid must be discarded. As a mandatory safety measure, the medicine must be kept out of the reach of children.